NTLA-2002

Intellia Therapeutics initiates HAELO Phase 3 study of NTLA-2002, a single-dose CRISPR-based gene editing therapy for hereditary angioedema (HAE), following positive Phase 1/2 data.

Intellia Therapeutics initiates HAELO, a global Phase 3 study of NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema (HAE). NTLA-2002 aims to prevent HAE attacks by inactivating the KLKB1 gene, with a single-dose treatment potential. The study follows positive Phase 1/2 data, showing significant attack rate reductions and durable kallikrein level reductions.

CRISPR technology, including CRISPR-Cas9, CRISPR-Cas12, and CRISPR-Cas13, is revolutionizing genome editing. FDA approved the first CRISPR-Cas9 drug, Casgevy®, for sickle cell disease and beta thalassemia. Other applications include treating urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, cardiovascular diseases, type 1 diabetes, systemic lupus erythematosus, HIV, and blood cancers. Challenges include cost, regulatory standards, and ethical considerations.

Intellia Therapeutics advances CRISPR-based therapies, with NTLA-2001 Phase 3 trials for ATTR amyloidosis progressing ahead of schedule. Plans to initiate NTLA-2001 Phase 3 for polyneuropathy by year-end. NTLA-2002 Phase 3 for HAE and NTLA-3001 Phase 1 for AATD to start in 2024. Ended Q1 2024 with $953M in cash.

The golden age of biotechnology is marked by scientific advances in disease treatment and prevention, offering investment opportunities. Key companies like Axsome Therapeutics, Exelixis, Intellia Therapeutics, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Twist Bioscience are leading with innovative drugs and technologies. The COVID-19 pandemic has further accelerated biotech advancements, especially in treatments and vaccines.